US FDA approves Strides' anti-anxiety drug

The US regulator nod for strides anti-anxiety drug Buspirone Hydrochloride tablets


market for generic Buspirone tablets was nearly $65 million

Strides Arcolab has announced that it has received approval from the United States Food and Drug Administration (US FDA) for its generic drug, Buspirone Hydrochloride tablets. The tablets are used for the treatment of anxiety disorders and the short-term relief from the symptoms of anxiety.

The approval has been granted for tablets in strengths 5 mg, 10 mg, 15 mg and 30 mg, the company informed. According to IMS data, the US market for generic Buspirone tablets was nearly $65 million in 2013.

"The product will be manufactured at the company's oral dosage facility at Bangalore and marketed directly by Strides in the US Market," the company said in a statement.




Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email